**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 13747**

**Columns: REVIEW**

**Anal cancer treatment: Current status and future perspectives**

Ghosn M *et al*. Current status and future perspectives of anal cancer treatment

Marwan Ghosn, Hampig Raphael Kourie, Pamela Abdayem, Joelle Antoun, Dolly Nasr

**Marwan Ghosn, Hampig Raphael Kourie, Pamela Abdayem, Joelle Antoun, Dolly Nasr,** Hematology-Oncology Department, Faculty Of Medicine, Saint Joseph University, Beirut, Lebanon

**Author contributions**: Ghosn M initiated the review; Abdayem P and Kourie HR performed the review and wrote and analyzed the data; Ghosn M, Antoun J, and Nasr D reviewed and commented on the paper and provided final approval.

**Open-Access:** This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Marwan Ghosn, MD,** Department of Oncology, Faculty of Medicine, Saint Joseph University, Monot Street, PO Box 166830, Beirut, Lebanon. mghosn.hdf@usj.edu.lb

**Telephone:** +961-3-226842

**Fax:** +961-1-613397

**Received:** August 30, 2014

**Peer-review started:** August 31, 2014

**First decision:** September 27, 2014

**Revised:**October 24, 2014

**Accepted:** December 20, 2014

**Article in press:**

**Published online:**

**Abstract**

Anal cancers (AC) are relatively rare tumors. Their incidence is increasing, however, particularly among men who have sex with other men due to widespread infection by human papilloma virus. The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage. In local and locally advanced AC, concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil (5-FU) is the current best treatment, whereasin metastatic AC, chemotherapy with 5-FU and cisplatin remains the gold standard. There are no indications for induction or maintenance therapies in locally advanced tumors. Many novel strategies, such as targeted therapies, vaccination, immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC, with promising results in some indications.

**Key words:** Anal cancer; Optimum treatment; Updates; Guidelines; Novel approaches

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This paper will be the newest study with the most recent updates in the treatment of anal cancer. After a brief review of different treatment of localized and metastatic anal cancer, the current options as well as novel therapies and approaches in future.

Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr D. Anal cancer treatment: Current status and future perspectives. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Anal cancers (AC) are relatively rare malignancies, representing less than 2.5% of all gastrointestinal (GI) cancers[1]. When localized, they usually have an acceptable prognosis, with a five-year survival of 80%[2].

The incidence of AC is currently increasing in men and women, particularly in men who have sex with other men, due to infection by human papilloma virus (HPV)[3]. Anal cancer is typically preceded by high-grade anal intraepithelial neoplasia (AIN grade 2 or 3)[4]. Factors reflecting a poor prognosis in AC include male sex, positive lymph nodes and a tumor size exceeding 5 cm[5].

According to the WHO classification, ACs are divided into lesions arising either from the anal canal (predominant squamous epithelium) or the anal margin (lined with skin). Given that the majority of anal cancers have a squamous histology, this paper focuses solely on squamous cell cancers of the anal canal.

The treatment of AC depends on the staging of the tumor and is based on radiation therapy (RT), chemotherapy (CT) and surgery. Local and locally advanced anal canal tumors are managed with a combination of CT and RT, whereaschemotherapy alone is generally used to treat metastatic disease. Surgery remains the standard of care for recurrent and residual disease.

This paper reports the latest updates on AC treatment present in the literature. It summarizes all of the important studies and trials concerning possible treatments in AC, highlights the currently approved treatment options and discusses novel approaches and therapies.

**EVOLUTION OF TREATMENT MODALITIES**

***Local and locally advanced AC***

Initially, non-metastatic tumors of the anal canal were treated with abdominoperineal resection (APR) and permanent colostomy, with a five-year survival of 40% to 70% and a perioperative mortality of 3%[6-13]. In 1974, Nigro *et al*[14] achieved complete pathological response in 3 patients using a combination of radiation therapy (30Gy) and chemotherapy that included mitomycin C (MMC) and 5-Fluorouracil (5-FU). Based on the findings of several studies and despite the absence of randomized trials comparing APR with radiation or chemoradiation (CRT), the use of concurrent RT with infusional 5-FU and MMC became the standard of care for patients with squamous cell anal cancer (SCAC), even those with T1-2 N0 disease. This treatment yielded five-year survival rates of 72% to 89%[15-21]. This combination has had a statistically significant impact on overall survival (OS), colostomy-free survival (CFS) and nodal relapse risk reduction[22]. Conversely, wide local excision can be a less morbid option for the management ofwell-differentiated T0 and early T1 tumors, if follow-up can be undertaken reliably[24,25], with cure rates reaching 60% at 5 years and local recurrences of approximately 40%[13,25,26].

The UK Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC) have conductedrandomized controlled trials to compare concurrent radiotherapy plus 5-FU and MMC with radiotherapy alone (Table 1). The EORTC trial reported a significantly lower colostomy rate, and both trials showed a significantly lower rate of locoregional failure in patients who received concurrent chemoradiation therapy. Overall survival was not significantly different between the groups in either trial. Fifteen of the 585 patients included in the UKCCCR trial had metastatic disease, and more patients in the CRT arm had T4 lesions or palpable nodes. CRT is therefore significantly superior to RT alone in terms of disease-free survival (DFS), local relapse, and CFS, but whether these benefits apply to early stage disease (T1-2, N0) remainsunclear[26,27].

In the Radiation Therapy Oncology Group (RTOG) 87-04 trial, which was conducted after the observation of increased hematologic toxicities with the use of MMC, significantly lower colostomy and local failure rates at 4 years were shown in patients who received the combination of radiotherapy with 5-FU plus MMC compared with those who received radiotherapy with 5-FU alone. Although the OS did not significantly differ between the groups, DFS was superior in the 5-FU and MMC group (73% *vs* 51% at 4 years; *P =* 0.0003)[29]. For the extremely elderly population with T1N0 tumors or those with significant comorbidities, the administration of 5-FU without MMC during RT may be considered[27].

In 2009, James *et al*[30] suggested that cisplatin might replace MMC in the treatment of non-metastatic anal cancer, with less hematologic toxicities and comparable response rates (RR), progression free survival (PFS), CFS, OS, and non-hematologic toxicities. However, these findings were not supported by the US intergroup RTOG 98-11 phase III trial, which showed significant differences favoring the combination of 5-FU and MMC in five-year DFS (68% *vs* 58%, *P =* 0.006) and OS (78% *vs* 71%, *P =* 0.026) after long-term follow-up[31,32]. Moreover, in 2013, James *et al*[33] published the results of arandomized, phase III, open label, 2 × 2 factorial, ACT II trial, which included 940 patients with non-metastatic SCAC and compared MMC and cisplatin CRT with or without maintenance chemotherapy. No evidence of any improvement in the complete response (CR) rate or three-year PFS was observed, and similar acute grade 3 and 4 toxic effects were reported when fluorouracil plus cisplatin CRT was compared with fluorouracil plus mitomycin CRT.

However, James *et al*[33] also showed that the three-year PFS, colostomy rate and OS were similar in the groups that did or did not receive maintenance chemotherapy with FU and cisplatin(*P =* 0.7).

Patients with T3/4 primary tumors or N2/3 disease are also managed with RT plus concomitant 5-FU and MMC, reaching cure rates of 50% to 60 %[34]. With radiotherapy alone, approximately 70% of inguinal nodes are controlled, whereas 90% of synchronous inguinal nodes are controlled with the addition of chemotherapy[26,35]. Other treatment options are listed in Table 2.

In 2005, in a population-based series of 308 patients, Nilsson *et al*[36] showed a significant benefit ofplatinum-based neoadjuvant chemotherapy in locally advanced anal cancer (LAAC). Induction chemotherapy with FU and cisplatin resulted in 8 CR and 21 partial responses (PR) in a phase II study by Meropol *et al*[38]. After induction and treatment with FU, MMC and RT, CR was achieved in 37 of the 45 patients (82%). However, neither the ACCORD 03 trial nor the RTOG 98-11 trial showed a benefit from the addition of induction chemotherapy to concurrent CRT[32,38].

The combination of radiation with MMC and cisplatin in LAAC was feasible, with an overall acceptable toxicity profile, according to 2 studies by Crehange *et al*[38] and Matzinger *et al*[40]. Phase III studies are needed. Epidermal growth factor receptor (EGFR) is expressed in 80% to 90% of cases of SCAC[41-43]. In addition, KRAS mutations, which confer resistance to anti-EGFR drugs, are almost absent in these tumors[41-44]. Clinical response to anti-EGFR drugs has been observed in single patients[45,46] and in small case series of patients[47], suggesting their potential effectiveness in this type of cancer. A phase I and a phase II studies of cetuximab in combination with 5-FU, cisplatin and RT in locally advanced SCAC were closed early due to serious adverse effects[48,49]. Further studies are therefore needed to identify acceptable doses of chemotherapy and radiotherapy in the neoadjuvant setting to reduce the risk of severe side-effects[49]. Although it has also been hypothesized that cetuximab could benefit patients with recurrent disease after chemoradiotherapy, few studies have been carried out in this area.

***Recurrent and residual disease***

A salvage APR is required in approximately 30% of cases, due to either primary non-response or the recurrence of anal cancer[51]. Tumors invading local structures often require multivisceral resection. Although the prognosis is poor overall, APR offers the potential for long-term survival[52-55]. Mullen *et al*[58] reported an overall actuarial survival rate of 64% in 31 patients with either persistent or recurrent SCAC treated with radical salvage surgery after a median follow-up of 29 mo. Important prognostic factors following resection include the presence of lymph node metastasis, treatment with a radiation dose of less than 55 Gy, status of the margins, a tumor size greater than 5 cm, adjacent organ involvement, male gender, and associated comorbidities. The use of intraoperative radiotherapy or brachytherapy may improve the local recurrence rates following radical resection when there is concern regarding an incomplete resection or close resection margins. In a study of 32 patients between 1993 and 2012, Hallemeier *et al*[59] showed that multimodality therapy, including salvage surgery and intraoperative radiotherapy, was associated with long-term survival (5-year OS: 23%, DFS 17%) in heavily pretreated patients with recurrent or residual anal cancer[57-59]. Flam *et al*[29] suggested the use of salvage CRT (9Gy along with 5-FU and cisplatin) in cases with residual disease following definitive CRT before a radical surgical approach, with an approximate 50% salvage rate in patients with biopsy-proven evidence of residual malignancy 4 to 6 wk after the completion of CRT.

***Metastatic disease***

Data concerningthe treatment of metastatic anal cancer aresparse in the literature due to the rarity of metastatic forms. The liver is the most common site of metastatic disease. The combination of cisplatin and 5-FU is considered the standard of care and the first-line regimen in metastatic disease, with overall response rates (ORR) of approximately 60%, most of which are partial responses, and a median survival of approximately 12 mo[60-64]. Other single agent or combination regimens used in this setting are listed in Table 3. Most of the data come from case reports using treatment regimens that are effective in other related malignancies, such as head and neck SCC, cervical cancer and GI cancers. Surgery has also been successfully used for extrapelvic metastases of SCAC, such as solitary brain and hepatic metastases[65,66].

Taxanes have established clinical activity in squamous cell cancer of the head and neckand in cervical cancer, both of which are strongly associated with HPV infection[67]. The study of their efficacy in SCAC is therefore interesting. In 2011, Golub *et al*[67] reported the results of the use of paclitaxel, ifosfamide and platinum in 3 patients with recurrent metastatic anal cancer who were previously treated with FU and cisplatin. They concluded that this regimen is highly active in this setting and, hopefully, in the treatment of selected high-risk patients with localized and potentially curable disease and that further studies should be conducted. Khawandanah *et al*[68] treated one metastatic anal cancer patient with paclitaxel, ifosfamide and cisplatin, achieving minimal residual disease. On progression five months after finishing therapy, the patient received mitomycin and cetuximab with mixed response after two cycles. Weekly paclitaxel was also used in 7 patients with metastatic SCAC after progression on FU and cisplatin,resulting in four objective responses and 1 stable disease[70]. In 2013, Kim *et al*[70] obtained 4 CR in 8 patients with recurrent advanced (metastatic) SCAC following the use of docetaxel, cisplatin and FU chemotherapy. Interestingly, all patients in CR had HPV-16-positive SCAC, whereas HPV could only be detected among 50% of the non-responding patients.

Chemotherapy regimens for GI cancers were also used in a few case reports. One patient with liver metastases and wild type KRAS treated with FOLFIRI and cetuximab had a PR after 6 cycles and an OS of 21 mo[45].In another case report, the use of the FOLFOX regimen in a single patient, followed by FOLFOX and panitumumab, then by FOLFIRI and panitumumab, markedly reduced the primary tumor with disappearance of the metastasis in the lung[46].

**CURRENT TREATMENT OPTIONS**

The standard of care in localized and locally advanced tumors of the anal canal remains concomitant radiotherapy and chemotherapy based on a continuous infusion of 1000 mg/m2/d of 5-FU (day 1 to 4 and 29 to 32), 10 mg/m2 of MMC (days 1 and 29) and a total radiation dose of 45 Gy divided into 22 sessions thatincludes the initial tumor and the inguinal lymph nodes[31]. There are no indications for induction or for maintenance chemotherapy[30,32].

Chemotherapy is the gold standard in treating metastatic AC and is based on the association of a continuous infusion of 5FU (1000 mg/m2/d, day 1 to 4) and cisplatin (100 mg/m2, day 2) every 4 wk[60].

HIV-positive patients should be treated similarly to non-HIV-positive individuals. Ideally, the viral load should be below 10000, and the CD4 count should be above 200[75-80]. Dosage adjustment and/or the omission of MMC can be considered in patients with active HIV/AIDS-related complications or a history of complications[81-84].

The combination of radiotherapy and chemotherapy in SCAC induces significant acute toxicities, with high rates of dermatitis and GI adverse effects. Subsequent effects include sexual dysfunction, lower limb venous thrombosis, proctitis, tenesmus, anal stenosis and bladder dysfunction[85]. These adverse effects usually require treatment breaks, which decrease the efficacy of radiation. Recent radiation techniques, such as intensity-modulated radiotherapy, minimize such adverse effects by decreasing the dose of radiation received by the normal surrounding structures[86].

**NOVEL APPROACHES AND THERAPIES**

In 2008, in a series of 118 HPV-positive patients with AIN or anal cancer, Walker *et al*[87] confirmed that human epidermal growth factor receptor 2 (HER2) is absent and that 96% of invasive carcinomas simultaneously expressed EGFR, c-Met, VEGFR1 and p16. These results are promising becausethey introduce potential new agents for the treatment of metastatic anal cancer, such as tyrosine kinase inhibitors (TKIs), anti-EGFR monoclonal antibodies, AMG102 (Monoclonal antibody against HGF, sole ligand of c-Met) and AEE788 (TKI of ErbB and VEGF pathways).

Gardini *et al*[44] analyzed the KRAS, BRAF and PIK3CA status in 50 patients with squamous cell anal carcinoma treated with concomitant CRT. Though the *KRAS* and *BRAF* genes were wild-type in all cases, the *PIK3CA* gene was mutated in 11 (22%) cases, suggesting that *PIK3CA* mutation may be involved in the process of carcinogenesis in some cases of SCAC and that this pathway may be used for targeted therapy against anal carcinoma. In another cohort study of 84 patients affected by SCAC, Martin *et al*[88] identified *PIK3CA* gene mutations in 16% of the cases. No mutations were found in the *BRAF* gene.

Rapamycin, an mTOR pathway inhibitor, was found to significantly slow, if not stop, the growth of anal cancer in two preclinical mouse models. The mTOR pathway is indeed activated in human squamous cell carcinomas, including those arising in the cervix and head/neck region, wherein HPV can be an etiological factor[89].

HPV causes 90% of squamous cell tumors of the anal canal[90,91]. In 2011, Palefsky *et al*[92] showed in a randomized controlled trial of healthy men who had sex with men between 16 and 26 years of age that a reduction in HPV 16/18 associated premalignant lesions (AIN 2/3) occurred with vaccination, without any vaccine-related serious adverse events. The efficacy of the vaccine at preventing anal dysplasia was higher in the per-protocol population (77.5%), which was HPV and dysplasia free (*i.e.*, prophylactic use) at the time of vaccination, than the intention-to-treat population (50.3%), which had active dysplasia or HPV infection, or had incident disease prior to completing the series. Vaccination might play a role in preventing reinfection if the natural clearance of HPV has occurred. Further studies on this topic are needed[93,94]. Per the Advisory Committee on Immunization Practices (ACIP) guidelines, the universal HPV vaccination of boys and girls at 11-12 years of age remains the most effective way to prevent future HPV-associated disease. The vaccine should also be offered to HIV-positive patients younger than 27 years of age and to older HIV-positive patients if they can afford it.

Photodynamic therapy (PDT), which consists of an infusion of Photofrin followed 48 h later by red light illumination, was suggested by Allison *et al*[95] in 2010 for the treatment of early anal cancer in select patients and of local failures. In their study, all 6 enrolled patients completed PDT without adverse effects and maintained local control of disease in the anal region for the length of follow up (18-48 mo).

Immunotherapy against the viral oncogenes, E6 and E7, of high-risk HPV subtypes, such as HPV-16 and HPV-18, is currently being studied. The use of an agent containing a segment of HPV-16 E7 protein for inducing an immune response against E7 appears to be both clinically feasible and safe[96]. A recombinant vaccine consisting of vaccinia virus MVA E2 induced a significant regression of high-grade cancer lesions in a phase II clinical trial. Other chimeric vaccines, such as VLP and L2, E7, E6 vaccines, are being also studied, and have yielded promising results[97].

**CONCLUSION**

The current treatment options in AC are well defined in locally advanced and metastatic disease with acceptable results. Many new strategies are being studied in these tumors, from targeted therapies to immunotherapy and photodynamic therapy. Vaccination, as a prevention strategy, might be the ideal means to decrease the incidence of anal cancer.

**REFERENCES**

|  |
| --- |
| 1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166].]  2 **Altekruse SF,** Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer statistics review 1975-2007. National Cancer Institute. Bethesda, MD, Available from: URL: http://seer.cancer.gov/csr/1975\_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010  3 **Johnson LG**, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. *Cancer* 2004; **101**: 281-288 [PMID: 15241824 DOI: 10.1002/cncr.20364].]  4 **Watson AJ**, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. *ANZ J Surg* 2006; **76**: 715-717 [PMID: 16916390 DOI: 10.1111/j.1445-2197.2006.03837.x]  5 **Gunderson LL**, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. *Int J Radiat Oncol Biol Phys* 2013; **87**: 638-645 [PMID: 24035327 DOI: 10.1016/j.ijrobp.2013.07.035]  6 **Singh R**, Nime F, Mittelman A. Malignant epithelial tumors of the anal canal. *Cancer* 1981; **48**: 411-415 [PMID: 7237411 DOI: 3.0.CO; 2-Z]  7 **Schraut WH**, Wang CH, Dawson PJ, Block GE. Depth of invasion, location, and size of cancer of the anus dictate operative treatment. *Cancer* 1983; **51**: 1291-1296 [PMID: 6825051 DOI: 3.0.CO; 2-R]  8 **Pintor MP**, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948 to 1984. *Br J Surg* 1989; **76**: 806-810 [PMID: 2765832 DOI: 10.1002/bjs.1800760814]  9 **Boman BM**, Moertel CG, O'Connell MJ, Scott M, Weiland LH, Beart RW, Gunderson LL, Spencer RJ. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. *Cancer* 1984; **54**: 114-125 [PMID: 6326995 DOI: 3.0.CO; 2-P]  10 **Klas JV**, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. *Cancer* 1999; **85**: 1686-1693 [PMID: 10223561 DOI: 3.0.CO; 2-7]  11 **Greenall MJ**, Quan SH, Stearns MW, Urmacher C, DeCosse JJ. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. *Am J Surg* 1985; **149**: 95-101 [PMID: 3966647 DOI: 10.1016/S0002-9610(85)80016-7]  12 **Dougherty BG**, Evans HL. Carcinoma of the anal canal: a study of 79 cases. *Am J Clin Pathol* 1985; **83**: 159-164 [PMID: 3969957]  13 **Klotz RG**, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. *Cancer* 1967; **20**: 1727-1745 [PMID: 6058180 DOI: 3.0.CO; 2-1]  14 **Nigro ND**, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. *Dis Colon Rectum* 1974; **17**: 354-356 [PMID: 4830803 DOI: 10.1007/BF02586980]  15 **Leichman L**, Nigro N, Vaitkevicius VK, Considine B, Buroker T, Bradley G, Seydel HG, Olchowski S, Cummings G, Leichman C. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. *Am J Med* 1985; **78**: 211-215 [PMID: 3918441 DOI: 10.1016/0002-9343(85)90428-0].]  16 **Doci R**, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. *J Clin Oncol* 1996; **14**: 3121-3125 [PMID: 8955657]  17 **Peiffert D**, Seitz JF, Rougier P, François E, Cvitkovic F, Mirabel X, Nasca S, Ducreux M, Hannoun-Levi JM, Lusinchi A, Debrigode E, Conroy T, Pignon JP, Gérard JP. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. *Ann Oncol* 1997; **8**: 575-581 [PMID: 9261527 DOI: 10.1023/A: 1008295119573].]  18 **Gerard JP**, Ayzac L, Hun D, Romestaing P, Coquard R, Ardiet JM, Mornex F. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. *Radiother Oncol* 1998; **46**: 249-256 [PMID: 9572617 DOI: 10.1016/S0167-8140(97)00192-8]  19 **Sischy B**, Doggett RL, Krall JM, Taylor DG, Sause WT, Lipsett JA, Seydel HG. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. *J Natl Cancer Inst* 1989; **81**: 850-856 [PMID: 2724350 DOI: 10.1093/jnci/81.11.850]  20 **Allal A**, Kurtz JM, Pipard G, Marti MC, Miralbell R, Popowski Y, Egeli R. Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. *Int J Radiat Oncol Biol Phys* 1993; **27**: 59-66 [PMID: 8365944 DOI: 10.1016/0360-3016(93)90421-Q]  21 **Martenson JA**, Lipsitz SR, Lefkopoulou M, Engstrom PF, Dayal YY, Cobau CD, Oken MM, Haller DG. Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. *Cancer* 1995; **76**: 1731-1736 [PMID: 8625041 DOI: 3.0.CO; 2-H]  22 **De Bari B**, Buglione M, Maddalo M, Lestrade L, Spiazzi L, Vitali P, Barbera F, Magrini SM. External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients. *Cancer Invest* 2014; **32**: 248-255 [PMID: 24766302 DOI: 10.3109/07357907.2014.907420]  23 **Leonard D**, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. *Clin Colon Rectal Surg* 2011; **24**: 54-63 [PMID: 22379406 DOI: 10.1055/s-0031-1272824]  24 **Heitland W**. [Diagnosis and therapy for anal carcinoma]. *Chirurg* 2008; **79**: 183-91; quiz 192 [PMID: 18227955 DOI: 10.1007/s00104-007-1453-y].]  25 **Greenall MJ**, Quan SH, Urmacher C, DeCosse JJ. Treatment of epidermoid carcinoma of the anal canal. *Surg Gynecol Obstet* 1985; **161**: 509-517 [PMID: 3934775]  26 **Hardcastle JD**, Bussey HJ. Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark's Hospital 1928-66. *Proc R Soc Med* 1968; **61**: 629-630 [PMID: 4173822]  27 **Northover J**, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). *Br J Cancer* 2010; **102**: 1123-1128 [PMID: 20354531 DOI: 10.1038/sj.bjc.6605605]  28 **Bartelink H**, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997; **15**: 2040-2049 [PMID: 9164216 DOI: 10.1016/S0360-3016(97)85445-4]  29 **Flam M**, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 1996; **14**: 2527-2539 [PMID: 8823332]  30 **James R**, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, Cunningham D, Meadows H, Ledermann J. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) (abstract # LBA4009). *J Clin Oncol* 2009; **27**: 797s  31 **Ajani J,** Winter K, Gunderson L, Pedersen J, Benson A, Thomas C, Mayer R, Haddock M, Rich T, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008; **299**: 1914 [DOI: 10.1001/jama.299.16.1914]  32 **Gunderson LL**, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol* 2012; **30**: 4344-4351 [PMID: 23150707 DOI: 10.1200/JCO.2012.43.8085]  33 **James RD**, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. *Lancet Oncol* 2013; **14**: 516-524 [PMID: 23578724 DOI: 10.1016/S1470-2045(13)70086-X]  34 **Das P**, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. *Int J Radiat Oncol Biol Phys* 2007; **68**: 794-800 [PMID: 17379452]  35 **Cohen AM**, Wong WD. Anal squamous cell cancer nodal metastases: prognostic significance and therapeutic considerations. *Surg Oncol Clin N Am* 1996; **5**: 203-210 [PMID: 8789503]  36 **Nilsson PJ**, Svensson C, Goldman S, Ljungqvist O, Glimelius B. Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. *Int J Radiat Oncol Biol Phys* 2005; **61**: 92-102 [PMID: 15629599]  37 **Meropol NJ**, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). *J Clin Oncol* 2008; **26**: 3229-3234 [PMID: 18490648 DOI: 10.1200/JCO.2008.16.2339]  38 **Peiffert D**, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012; **30**: 1941-1948 [PMID: 22529257 DOI: 10.1200/JCO.2011.35.4837]  39 **Crehange G**, Bosset M, Lorchel F, Dumas JL, Buffet-Miny J, Puyraveau M, Mercier M, Bosset JF. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. *Dis Colon Rectum* 2007; **50**: 43-49 [PMID: 17089083 DOI: 10.1007/s10350-006-0761-5]  40 **Matzinger O**, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). *Eur J Cancer* 2009; **45**: 2782-2791 [PMID: 19643599 DOI: 10.1016/j.ejca.2009.06.020]  41 **Paliga A**, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? *Br J Cancer* 2012; **107**: 1864-1868 [PMID: 23093229 DOI: 10.1038/bjc.2012.479]  42 **Zampino MG**, Magni E, Sonzogni A, Renne G. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? *Cancer Chemother Pharmacol* 2009; **65**: 197-199 [PMID: 19727729 DOI: 10.1007/s00280-009-1117-3]  43 **Van Damme N**, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. *BMC Cancer* 2010; **10**: 189 [PMID: 20459770 DOI: 10.1186/1471-2407-10-189]  44 **Casadei Gardini A**, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S, Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). *PLoS One* 2014; **9**: e92071 [PMID: 24642661 DOI: 10.1371/journal.pone.0092071]  45 **Barmettler H**, Komminoth P, Schmid M, Duerr D. Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. *Case Rep Oncol* 2012; **5**: 428-433 [PMID: 22949905 DOI: 10.1159/000341371]  46 **Bamba T**, Suda T, Nakano M, Terashima T, Umezu H. [Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - a case report]. *Gan To Kagaku Ryoho* 2012; **39**: 311-315 [PMID: 22333651]  47 **Lukan N**, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. *Oncology* 2009; **77**: 293-299 [PMID: 19923868 DOI: 10.1159/000259615]  48 **Olivatto LO,** Meton F, Bezerra M, Cardoso A, Araujo CM, Castro L, Moura R, Pereira BV, Ferreira CG. Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). *J Clin Oncol*; suppl 243: Abstract 4609  49 **Deutsch E**, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. *Ann Oncol* 2013; **24**: 2834-2838 [PMID: 24026540 DOI: 10.1093/annonc/mdt368]  50 **Eng C**, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. *Cancer* 2013; **119**: 3769-3775 [PMID: 24037775 DOI: 10.1002/cncr.28296]  51 **Goto H**, Ikenaga M, Yasui M, Miyazaki M, Mishima H, Tsujie M, Miyamoto A, Hirao M, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T. [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. *Gan To Kagaku Ryoho* 2010; **37**: 2659-2661 [PMID: 21224671]  52 **Eeson G**, Foo M, Harrow S, McGregor G, Hay J. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. *Am J Surg* 2011; **201**: 628-633 [PMID: 21545912 DOI: 10.1016/j.amjsurg.2011.01.015]  53 **Lefèvre JH**, Corte H, Tiret E, Boccara D, Chaouat M, Touboul E, Svrcek M, Lefrancois M, Shields C, Parc Y. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. *Ann Surg Oncol* 2012; **19**: 4186-4192 [PMID: 22825769 DOI: 10.1245/s10434-012-2485-1]  54 **Correa JH**, Castro LS, Kesley R, Dias JA, Jesus JP, Olivatto LO, Martins IO, Lopasso FP. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. *J Surg Oncol* 2013; **107**: 486-492 [PMID: 23129564 DOI: 10.1002/jso.23283]  55 **Cunin L**, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T. Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals. *Ann Surg Oncol* 2014; **21**: 527-532 [PMID: 24242676 DOI: 10.1245/s10434-013-3353-3]  56 **Allal AS**, Laurencet FM, Reymond MA, Kurtz JM, Marti MC. Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. *Cancer* 1999; **86**: 405-409 [PMID: 10430247]  57 **Schiller DE**, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. *Ann Surg Oncol* 2007; **14**: 2780-2789 [PMID: 17638059]  58 **Mullen JT**, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. *Ann Surg Oncol* 2007; **14**: 478-483 [PMID: 17103253 DOI: 10.1245/s10434-006-9221-7]  59 **Hallemeier CL**, You YN, Larson DW, Dozois EJ, Nelson H, Klein KA, Miller RC, Haddock MG. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. *Dis Colon Rectum* 2014; **57**: 442-448 [PMID: 24608300 DOI: 10.1097/DCR.0000000000000071]  60 **Faivre C**, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. *Bull Cancer* 1999; **86**: 861-865 [PMID: 10572237]  61 **Jaiyesimi IA**, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. *Am J Clin Oncol* 1993; **16**: 536-540 [PMID: 8256774 DOI: 10.1097/DCR.0000000000000071x]  62 **Tanum G**. Treatment of relapsing anal carcinoma. *Acta Oncol* 1993; **32**: 33-35 [PMID: 8466762 DOI: 10.3109/02841869309083882]  63 **Khater R**, Frenay M, Bourry J, Milano G, Namer M. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. *Cancer Treat Rep* 1986; **70**: 1345 [PIMD: 3768879]  64 **Ajani JA**, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. *Am J Med* 1989; **87**: 221-224 [PMID: 2527006 DOI: 10.1016/S0002-9343(89)80702-8]  65 **Rughani AI**, Lin C, Tranmer BI, Wilson JT. Anal cancer with cerebral metastasis: a case report. *J Neurooncol* 2011; **101**: 141-143 [PMID: 20440537 DOI: 10.1007/s11060-010-0218-5]  66 **Tokar M**, Bobilev D, Zalmanov S, Geffen DB, Walfisch S. Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. *Onkologie* 2006; **29**: 30-32 [PMID: 16514253 DOI: 10.1159/000089798]  67 **Golub DV**, Civelek AC, Sharma VR. A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. *Chemother Res Pract* 2011; **2011**: 163736 [PMID: 22295202 DOI: 10.1155/2011/163736]  68 **Khawandanah M**, Baxley A, Pant S. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. *J Oncol Pharm Pract* 2014 Mar 13 [PMID: 24627343 DOI: 10.1177/1078155214526268]  69 **Abbas A**, Nehme E, Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. *Anticancer Res* 2011; **31**: 4637-4640 [PMID: 22199342]  70 **Kim S**, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, Nguyen T, Kaliski A, Delabrousse E, Bonnetain F, Letondal P, Bosset JF, Valmary-Degano S, Borg C. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. *Ann Oncol* 2013; **24**: 3045-3050 [PMID: 24114858 DOI: 10.1093/annonc/mdt396]  71 **Jhawer M**, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, Haller D. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. *Invest New Drugs* 2006; **24**: 447-454 [PMID: 16763788 DOI: 10.1007/s10637-006-7667-x]  72 **Nitori N**, Kato Y, Kato A, Deguchi T, Okada A, Kojima M, Kuroda J, Kadomura T, Kubota K, Origuchi N, Fujisaki M, Kitajima M. Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer. *Anticancer Res* 2011; **31**: 3983-3989 [PMID: 22110231]  73 **Oehler-Jänne C**, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2008; **26**: 2550-2557 [PMID: 18427149 DOI: 10.1200/JCO.2007.15.2348]  74 **Edelman S**, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. *Int J Radiat Oncol Biol Phys* 2006; **66**: 206-211 [PMID: 16904522 DOI: 10.1016/j.ijrobp.2006.03.049]  75 **Cleator S**, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. *Eur J Cancer* 2000; **36**: 754-758 [PMID: 10762748 DOI: 10.1016/S0959-8049(00)00009-5]  76 **Chiao EY**, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. *J Clin Oncol* 2008; **26**: 474-479 [PMID: 18202423 DOI: 10.1200/JCO.2007.14.2810]  77 **Seo Y**, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. *Int J Radiat Oncol Biol Phys* 2009; **75**: 143-149 [PMID: 19203845 DOI: 10.1016/j.ijrobp.2008.10.046]  78 **Fraunholz I,** Rabeneck D, Gerstein J, Jäck K, Haberl A, Weiss C, Rödel C. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? *Radiother Oncol* 2011; **98**: 99 [PMID:21168927 ; DOI:10.1016/j.radonc.2010.11.011]  79 **Wexler A**, Berson AM, Goldstone SE, Waltzman R, Penzer J, Maisonet OG, McDermott B, Rescigno J. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. *Dis Colon Rectum* 2008; **51**: 73-81 [PMID: 18066626 DOI: 10.1007/s10350-007-9154-7]  80 **Kauh J**, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR. Management of anal cancer in the HIV-positive population. *Oncology (Williston Park)* 2005; **19**: 1634-168; discussion 1634-168; 1645 passim [PMID: 16396154]  81 **Hoffman R**, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. *Int J Radiat Oncol Biol Phys* 1999; **44**: 127-131 [PMID: 10219805 DOI: 10.1016/S0360-3016(98)00528-8]  82 **Place RJ**, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. *Dis Colon Rectum* 2001; **44**: 506-512 [PMID: 11330577 DOI: 10.1007/BF02234322]  83 **Stadler RF**, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. *Dis Colon Rectum* 2004; **47**: 1305-1309 [PMID: 15484343 DOI: 10.1007/s10350-004-0584-1]  84 **National Comprehensive Cancer Network (NCCN)**. NCCN Clinical practice guidelines in oncology. Accessed on 2014, May 26. Available from: URL: http: //www.nccn.org/professionals/physician\_gls/f\_guidelines.asp  85 **Zampino MG**, Magni E, Leonardi MC, Santoro L, Petazzi E, Fodor C, Petralia G, Trovato C, Nolè F, Orecchia R. Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. *BMC Cancer* 2011; **11**: 55 [PMID: 21291546 DOI: 10.1186/1471-2407-11-55]  86 **Salama JK**, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. *J Clin Oncol* 2007; **25**: 4581-4586 [PMID: 17925552 DOI: 10.1200/JCO.2007.12.0170]  87 **Walker F**, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. *Hum Pathol* 2009; **40**: 1517-1527 [PMID: 19716155 DOI: 10.1016/j.humpath.2009.05.010]  88 **Martin V**, Zanellato E, Franzetti-Pellanda A, Molinari F, Movilia A, Paganotti A, Deantonio L, De Dosso S, Assi A, Crippa S, Boldorini R, Mazzucchelli L, Saletti P, Frattini M. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. *Histol Histopathol* 2014; **29**: 513-521 [PMID: 24122611]  89 **Stelzer MK**, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. *Cancer Prev Res (Phila)* 2010; **3**: 1542-1551 [PMID: 21149330 DOI: 10.1158/1940-6207]  90 **Parkin DM**. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006; **118**: 3030-3044 [PMID: 16404738 DOI: 10.1002/ijc.21731]  91 **Forman D,** de Martel C, Lacey C, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. *Vaccine* 30 Suppl 5 2012; F12–F23 [DOI: 10.1016/j.vaccine.2012.07.055]  92 **Palefsky JM**, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011; **365**: 1576-1585 [PMID: 22029979 DOI: 10.1056/NEJMoa1010971]  93 **Olsson SE**, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Hum Vaccin* 2009; **5**: 696-704 [PMID: 19855170 DOI: 10.4161/hv.5.10.9515]  94 **Joura EA**, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ* 2012; **344**: e1401 [PMID: 22454089 DOI: 10.1136/bmj.e1401]  95 **Allison RR**, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH. Photodynamic therapy for anal cancer. *Photodiagnosis Photodyn Ther* 2010; **7**: 115-119 [PMID: 20510306 DOI: 10.1016/j.pdpdt.2010.04.002]  96 **García-Hernández E**, González-Sánchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, Jiménez R, Reyes L, Morosoli G, Verde ML, Rosales R. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. *Cancer Gene Ther* 2006; **13**: 592-597 [PMID: 16456551]  97 **Kaufmann AM**, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). *Int J Cancer* 2007; **121**: 2794-2800 [PMID: 17721997 DOI: 10.1002/ijc.23022] |

**P-Reviewer:** Araujo A, Kukongviriyapan V, Zou CL **S-Editor:** Yu J

**L-Editor: E-Editor:**

**Table 1 Results of different treatment modalities in localized squamous cell anal cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Protocol** | **CR** | **CFS** | **OS** | **DFS** |
| A | RT | 54%[29] | 32% lower colostomy-free rate than C[28] | 14% higher death rate than C[27] | 12.9% higher death and relapse rates at 5 yr than C[27] |
| B | RT + 5-FU | NA | 71%[29] | No significant difference from C | 51%[29] |
| C | RT + 5-FU + Mitomycin | 80%[29]  89.6% at 26 wk[34] | 59%[28] | 78.3% at 5 yr[32,33] | 67.8%[29,30]  to 73%[29] |
| D | RT + 5-FU + Cisplatin | 90.5% at 26 wk[34] | NA | 70.7% at 5 yrs[31,32] | 57.8%[31,32] |

NA: Not availiable; RT: Radiation therapy; 5-FU: 5-Fluorouracil; CR: Complete response; CFS: Colostomy-free survival; OS: Overall survival; DFS: Disease free survival.

**Table 2 Studies evaluating recent treatment options in locally advanced anal cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Study** | **Patients, *n*** | **Protocol** | **RR** | **OS** | **DFS** | **CFS** |
| Induction chemotherapy in LAAC | Nilsson *et al*[36], 2005  Population-based series | 308 invasive SCAC  142 locally advanced | - Arm A: Neoadjuvant platinum CT followed by RT alone  -Arm B: RT with or without Bleomycin | CR: 92%  CR: 76%  *P* < 0.01 | 63%  44% *P* < 0.05 | NA | NA |
| Meropol *et al*[37], 20081  Phase II | 45 | Induction: 2 28-d cycles (FU + cisplatin) followed by 2 28-d cycles (FU + mitomycin) with concurrent split-course radiation | CR: 82% | 68% at 4 yr | 61% at 4 yr | 50% |
| Peiffert *et al*[38], 20122  Phase III RCT | 283 | -Arm A: 2 ICT cycles (5-FU + cisplatin) then RCT and standard dose boost (SD: 15 Gy)  -Arm B: 2 ICT, RCT and high dose boost (HD: 20-25 Gy)  -Arm C: RCT and SD boost  -Arm D: RCT and HD boost | NA | NA | NA | 69.6%  82.4%  77.1%  72.7% |
| Combination of MMC and cisplatin in LAAC | Crehange *et al*[39], 2007  Phase II | 21 | 1st sequence:RT 36 Gy over 4 wk  2nd sequence: 23.4 Gy over 2.5 wk, gap 16 d  MMC and CDDP | CR: 90.5% | NA | NA | NA |
| Matzinger *et al*[40], 20093  Phase II | 80 | RT: 36Gy+2 week gap+23.4 Gy  -Arm A: MMC + Cisplatin + RT  -Arm B: MMC + 5-FU +RT | RR: 91.9%  RR: 79.5% | NA | NA | NA |
| Targeted therapy in LAAC | Olivatto *et al*[48], 2013  Phase I | 21 | Cetuximab + RT + 5-FU + cisplatin | pCR: 95% | NA | NA | NA |
| Deutsch *et al*[49], 2013  Phase II | 16 | Cetuximab + RT + 5-FU + cisplatin | CR: 55%  PR: 45% | 92% at 1 yr | NA | 67% at 1 yr |
| Cisplatin in LAAC | Eng *et al*[50], 20134  Retrospective single institution analysis | 197 (41% stage II, 46% stage III, 24% N2-N3) | Weekly (20 mg/m2) or daily (4 mg/m2) cisplatin with 5-FU and RT | CR: 94% | 86% at 5 yr | 81% at 5 yr | 88% at 5 yr |

1After induction, 8 CR and 21 PR. A third cycle of FU and cisplatin with radiation boost was given to patients with persistent primary site disease or bulky N2 or N3 disease at presentation; 2Considering the 2 × 2 factorial analysis, the 5-year CFS was 76.5% *vs* 75% in groups A and B *vs* C and D, respectively (ICT effect; *P* = 0.37), and 73.7% *vs* 77.8% in groups A and C *vs* B and D, respectively (RT-dose effect; *P* = 0.067); 3In the first arm, 9 patients discontinued treatment, with 9 grade 3 hematologic effects. In the second arm, 2 discontinued treatment, and no grade 3 hematologic effects were reported; 4The local recurrence rate was 11% after the median follow-up of 8.6 yr, and 8% of the patients developed distal metastases. LAAC: Locally advanced anal cancer; MMC: Mitomycin C; RR: Response rate; NA: Not availiable; RT: Radiation therapy; 5-FU: 5-Fluorouracil; CR: Complete response; CFS: Colostomy-free survival; OS: Overall survival; DFS: Disease free survival; RT: Radiation therapy.

**Table 3 Recent case reports and case series evaluating treatment in metastatic anal cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Number of patients** | **Characteristics of patients** | **Regimen** | **Response** | **Survival** |
| Jhawer *et al*[71], 2006 | 20  Phase II |  | MMC, adriamycin, cisplatin followed by bleomycin-CCNU upon progression of disease | 60% PR  0% CR | 15 mo |
| Golub *et al*[67], 2011 | 3  P1  P2  P3 | Previously treated with 5-FU and cisplatin | Paclitaxel 175mg/m2 on D1  Ifosfamide 1g/m2 D1 to D4  Cisplatin 75mg/m2 on D1  Every 3 wk | CR in 3 patients  Response duration  6 mo  2.5 yr  4 mo | Survival since recurrence  14 mo  30 mo  17 mo (patient still alive) |
| Abbas *et al*[69], 2011 | 7 | Prior progression on cisplatin and 5-FU | Weekly paclitaxel | 1 CR, 3PR,  1 SD | 12-14 mo1 |
| Kim *et al*[70], 2013 | 8 | Advanced recurrent | Docetaxel 75 mg/m2 day 1, CDDP 75 mg/m2 day 1 and 5FU at 750 mg/m(2)/day for 5 d every 3 wk | CR: 50% | OS 62.5% at 12 mo |
| Khawandanah *et al*[68], 2014 | 1 | Skin and perianal metastasis | (1) Paclitaxel, ifosfamide, cisplatin (4 cycles) followed by  (2) Mitomycin, cetuximab (2 cycles) | 1) Minimal residual disease  2) Mixed response | (1) Progression 5 mo after the end of therapy  (2) OS 24 mo; 16 mo after paclitaxel was started |
| Barmettler *et al*[45], 2012 | 1 | Liver metastasis, KRAS wild type and EGFR 2 + | FOLFIRI + cetuximab | Partial response after 6 cycles | 21 mo |
| Bamba *et al*[46], 2012 | 1 | Lung metastasis | 3 FOLFOX🡺3 courses of FOLFOX + panitumumab🡺 5 courses of FOLFIRI + panitumumab | Marked reduction of primary tumor, disappearance of lung metastasis. | The patient underwent low anterior resection.  No recurrence after 5 mo |
| Lukan *et al*[47], 2009  Case report | 7 | First or subsequent treatment line | Cetuximab alone or with irinotecan first or subsequent line. KRAS mutated in 2/7 | PR 3  MR 1  PD 2 (Mutated kras)  SD 1 | NA |
| Nitori *et al*[72], 2011 | 1 | 58-yr-old female | Oral S-1 (120 mg/body; day 1-21) + low dose cisplatin (10 mg/body; day 1-5, 8-12) + RT for 2 cycles then rest for 4 wk | CR of the primary lesion and PR for the metastatic lesions | 16 mo |

1Duration of clinical benefit in SD and PR after the initiation of Paclitaxel: 4-6 mo. PD: Progressive disease; PR: Partial response; MR: Minor response; SD: Stable disease; NA: Not availiable.